Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4154-4162

  Wentzensen, Nicolas ^a   Schwartz, Lauren ^a   Zuna, Rosemary E ^b   Smith, Katie ^b   Mathews, Cara ^b   Gold, Michael A ^c   Allen, R Andy ^b   Zhang, Roy ^b   Dunn, S Terence ^b   Walker, Joan L ^b   Schiffman, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATYPICAL SQUAMOUS CELL OF UNDETERMINED SIGNIFICANCE; COLPOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HPV DNA TESTING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTIONS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84864459633     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0270     Document Type: Article

References (21)

1. Schiffman M, Wentzensen N. From human papillomavirus to cervical cancer. Obstet Gynecol 2010;116:177-85.
2. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
3. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol 2011;6:1083-98.
4. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007;23:297-313.
5. Wentzensen N, von Knebel DM. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315-30.
6. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536-45.
7. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210-20.
8. Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, von Knebel DM. Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005;105:461-7.
9. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011;121:505-9.
10. Schmidt D, Bergeron C, Denton KJ, Ridder R. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011;119:158-66.
11. Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev 2009;18:113-20.
12. Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009;124:964-9.
13. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
14. van BM, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 1997;76:651-7.
15. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387-96.
16. Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-6.
17. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011;20:1398-409.
18. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
19. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
20. Carozzi F, Confortini M, Dalla PP, Del MA, Gillio-Tos A, De ML, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9:937-45.
21. Grabe N, Lahrmann B, Pommerencke T, von Knebel DM, Reuschenbach M, Wentzensen N. A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. Cell Oncol 2010;32:109-19.